/HLVX
HLVX Stock - HilleVax, Inc.
Healthcare|BiotechnologyNASDAQ
$2.09-0.48%
$0.01 (-0.48%) • Sep 17
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.63
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.89
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1431.1%upside
Target: $32.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HLVX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.07 – $2.11
TARGET (TP)$32.00
STOP LOSS$1.92
RISK/REWARD1:175.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.77
52W High$2.17
52W Low$1.34
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-2,156,000 | $-2,252,000 | $-3,000 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-155,291,000 | $-133,345,000 | $-65,113,000 | $-53,426,000 | $-1,295,000 |
| Net Income | $-147,267,000 | $-123,566,000 | $-257,005,000 | $-85,025,000 | $-2,132,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.00 | $-3.04 | $-6.83 | $-2.82 | $-0.07 |
Company Overview
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
50%
Hold / Neutral
4
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
4 Bullish4 Neutral/Bearish
Price Targets
$19
Average Target
↑ 793.1% Upside
Now
$2
Low
$19
Average
$40
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 9th 2024 | Leerink Partners | Downgrade | Market Perform | $2← $28 |
| July 9th 2024 | Stifel | Downgrade | Hold | $3← $34 |
| July 9th 2024 | H.C. Wainwright | Downgrade | Neutral | $2← $28 |
| July 8th 2024 | Guggenheim | Downgrade | Neutral | - |
| July 8th 2024 | JP Morgan | Downgrade | Neutral | $5← $24 |
| December 13th 2023 | H.C. Wainwright | Initiation | Buy | $28 |
| May 24th 2022 | JP Morgan | Initiation | Overweight | $24 |
| May 24th 2022 | Stifel | Initiation | Buy | $34 |
| May 24th 2022 | SVB Leerink | Initiation | Outperform | $30 |
| May 24th 2022 | Guggenheim | Initiation | Buy | $40 |
Earnings History & Surprises
HLVXBeat Rate
53%
Last 15 quarters
Avg Surprise
-23.5%
EPS vs Estimate
Beats / Misses
8/7
Last 12 quarters
Latest EPS
$-0.52
Q4 2025
EPS Surprise History
Q1 24
+6.0%
$-0.78vs$-0.83
Q2 24
-15.5%
$-0.97vs$-0.84
Q3 24
-6.4%
$-0.83vs$-0.78
Q4 24
-23.8%
$-0.52vs$-0.42
Q1 25
-6.1%
$-0.35vs$-0.33
Q2 25
+67.6%
$-0.12vs$-0.37
Q3 25
+21.4%
$-0.11vs$-0.14
Q4 25
-246.7%
$-0.52vs$-0.15
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 6, 2025 | $-0.15 | $-0.52 | -246.7% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.14 | $-0.11 | +21.4% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.37 | $-0.12 | +67.6% | ✓ BEAT |
Q1 2025 | Mar 28, 2025 | $-0.33 | $-0.35 | -6.1% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.42 | $-0.52 | -23.8% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.78 | $-0.83 | -6.4% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.84 | $-0.97 | -15.5% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $-0.83 | $-0.78 | +6.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.84 | $-0.81 | +3.6% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.90 | $-0.74 | +17.8% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.94 | $-0.71 | +24.5% | ✓ BEAT |
Q1 2023 | Mar 17, 2023 | $-1.46 | $-0.56 | +61.6% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.91 | $-0.45 | +50.5% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.87 | $-2.03 | -133.3% | ✗ MISS |
Q2 2022 | Jun 8, 2022 | $-3.67 | $-10.06 | -174.1% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-1.24 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-2.05 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.06 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.05 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.02 | — | — |
Latest News
Loading news...
Frequently Asked Questions about HLVX
What is HLVX's current stock price?
HilleVax, Inc. (HLVX) is currently trading at $2.09 per share. The stock has moved -0.48% today.
What is the analyst price target for HLVX?
The average analyst price target for HLVX is $32.00, based on 1 analyst.
What sector is HilleVax, Inc. in?
HilleVax, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is HLVX's market cap?
HilleVax, Inc. has a market capitalization of $0.10 billion, making it a small-cap company.
Does HLVX pay dividends?
No, HilleVax, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAADI
Aadi Bioscience, Inc.
$2.05
Mkt Cap: $0.1B
BLI
Berkeley Lights, Inc.
$1.20
Mkt Cap: $0.1B
CYT
Cyteir Therapeutics, Inc.
$3.02
Mkt Cap: $0.1B
DBTX
Decibel Therapeutics, Inc.
$4.91
Mkt Cap: $0.1B
IMDX
Insight Molecular Diagnostics Inc.
$5.41
Mkt Cap: $0.2B
JNCE
Jounce Therapeutics, Inc.
$1.88
Mkt Cap: $0.1B
MIRO
Miromatrix Medical Inc.
$3.39
Mkt Cap: $0.1B
OPNT
Opiant Pharmaceuticals, Inc.
$20.65
Mkt Cap: $0.1B
RVLP
RVL Pharmaceuticals plc
$0.03
Mkt Cap: $0.0B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
Explore stocks similar to HLVX for comparison